Neonatal coagulation disorders and thromboembolism require timely management. Failure to treat these conditions at the appropriate time may lead to death or the development of significant long-term sequelae. However, most current guidelines for managing neonatal coagulation disorders and thromboembolism are empiric and not based on randomized clinical trials. Thus, it is not easy to choose an appropriate management strategy for these conditions in clinical settings. In this review, therapeutic guidelines currently utilized in clinics and novel therapeutic options still under investigation are presented and reviewed.
Humans ; Infant, Newborn ; Thromboembolism ; Thrombolytic Therapy

Humans ; Pulmonary Embolism ; diagnosis ; therapy ; Venous Thromboembolism ; diagnosis ; therapy

China ; epidemiology ; Humans ; Venous Thromboembolism ; diagnosis ; drug therapy ; epidemiology

Humans ; Factor XI ; Thromboembolism/drug therapy* ; Anticoagulants/therapeutic use*

Humans ; China ; Consensus ; Purpura, Thrombocytopenic, Idiopathic/therapy* ; Thrombocytopenia/therapy* ; Thromboembolism/therapy*

BACKGROUND/AIMS: The mortality rate following massive and submassive pulmonary embolism (PE) remains high despite thrombolytic therapy. Although thrombolytic therapy is considered a life-saving intervention in massive PE, it is only selectively indicated in patients without hypotension who are at high risk of developing hypotension. Little is known about its clinical outcome in Korea. METHODS: We retrospectively reviewed the records of patients given thrombolytics for massive and submassive PE objectively confirmed with chest computed tomography at Soon Chun Hyang University Hospital, Seoul, Korea, from 1 January 2004 to 1 August 2011. The primary outcome of this study was 30-day mortality. Secondary outcomes were the incidence of major bleeding at 30 days, mortality at 90 days, and recurrent venous thromboembolism (VTE) at 90 days. RESULTS: Thrombolytic therapy was performed in 21 patients: nine with massive and 12 with submassive PE. The overall 30-day mortality rate was 24% (5/21). The mortality rate in patients with massive PE was higher than that in patients with submassive PE (44% vs. 8%, respectively; p = 0.010). Mortality rates at 90 and 30 days were identical. The estimated causes of death were right ventricular failure in four patients and fatal bleeding in one patient. The median time to death from thrombolysis was 1 day (0-13 days). Major bleeding episodes occurred in three patients (14%), including fatal bleeding in one patient. There was no recurrent VTE at 90 days. CONCLUSIONS: Patients who underwent thrombolytic therapy for massive PE showed a higher 30-day mortality compared with patients with submassive PE.
Cause of Death ; Hemorrhage ; Humans ; Hypotension ; Incidence ; Korea ; Pulmonary Embolism ; Retrospective Studies ; Thorax ; Thrombolytic Therapy ; Venous Thromboembolism

Six cases of bileaflet mechanical mitral valve thrombosis were serially assessed by Doppler echocardiography and cinefluoroscopy during thrombolytic therapy with urokinase. Two patients had dual mechanical valve replacement in the aortic and mitral positions simultaneously. Bileaflet thrombosis was diagnosed by 2-dimensional echocardiography in three cases, Doppler echocardiography and cinefluoroscopy in six cases. Thrombolytic therapy using urokinase was successful in five patients (3 cases : UK 1,000,000 unit x 3 hours for 2 days, 2 cases ; UK 1,000,000 unit/24 hours for 5 and 7 days respecitively, 1 case ; UK 1,000,000 unit/hr x 3 hours for 1 day). The other one patients had massive cerebral thromboembolism and subsequently died. These study demonstrated the usefulness of Doppler echocardiography and cinefluoroscopy in diagnosis and serial assessment of thrombolytic therapy in the patients with mechanical mitral valve thrombosis.
Diagnosis* ; Echocardiography ; Echocardiography, Doppler ; Humans ; Mitral Valve* ; Thromboembolism ; Thrombolytic Therapy* ; Thrombosis* ; Urokinase-Type Plasminogen Activator*

Lung cancer patients have increased risk of thromboembolism (TE) due to various factors such as by hypercoagulability, tumor thrombosis, decrease of ambulation, and chemotherapy etc. Among these factors, chemotherapy associated TEs have been reported, although the causes and pathomechanisms of TEs were not clear. Recently, reports proposed the potential role of platelets in endothelial damage by the chemotherapeutic agents. We have experienced a case of pulmonary TE after systemic chemotherapy with gemcitabine and cisplatin. The patient complained aggravated exertional dyspnea after chemotherapy and diagnosed as pulmonary TE by computerized tomogram. After anticoagulation and interruption of the chemotherapy, improvement of exertional dyspnea and resolution of the pulmonary TE were observed
Cisplatin* ; Drug Therapy* ; Dyspnea ; Humans ; Lung Neoplasms* ; Lung* ; Pulmonary Embolism* ; Thromboembolism ; Thrombophilia ; Thrombosis ; Walking

Thalassemia is the most common human hereditary hemolytic anemia. Due to splenomegaly and hypersp-lenism, splenectomy can be used as a means of treatment for thalassemia. Various complications following splenectomy, however, especially thromboembolic complications are remarkable. This review summarizes the incidence, clinical manifestations and development time of thromboembolism. The pathogenesis of thromboembolism after splenectomy in thalassemia, such as abnormal platelet number and function, changes in red cell membrane, endothelial cell damage, dysfunction of other procoagulant and anticoagulant factors, and local factors associated with splenectomy are elaborated and the trategies to prevent and treat the thromboembolic events in thalassemia after splenectomy, including the attention to risk factors associated with splenectomy, a reassessment of splenectomy, regular blood transfusion to reduce the ratio of abnormal red blood cells, treatment with anticoagulant and antiplatelet drugs, application of hydroxyurea and stem cell transplantation are discussed.
Anticoagulants ; therapeutic use ; Blood Transfusion ; Humans ; Risk Factors ; Splenectomy ; Thalassemia ; pathology ; Thromboembolism ; pathology ; prevention & control ; therapy

Anticoagulants ; therapeutic use ; Atrial Fibrillation ; etiology ; genetics ; therapy ; Catheter Ablation ; Humans ; Thromboembolism ; prevention & control ; United States